The microenvironment in chronic lymphocytic leukemia: Biology and therapeutic translation

Pietro Bulian, Jan Burger

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The recent success of kinase inhibitors targeting the B cell receptor downstream molecules BTK (ibrutinib and PI3K (idelalisib), their characteristic clinical activity with chronic lymphocytic leukemia (CLL) cell redistribution from tissues into the blood, and their unique mechanism, interception of critical CLL - microenvironment interactions and signaling pathways, emphasize that the CLL microenvironment is a critical player in CLL pathogenesis and key for development of new targeted treatment approaches.

Original languageEnglish
Title of host publicationHodgkin and Non-Hodgkin Lymphomas Seen through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy
PublisherFuture Medicine Ltd.
Pages56-71
Number of pages16
Volume2
ISBN (Print)9781780845821, 9781780845845
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Phosphatidylinositol 3-Kinases
B-Lymphocytes
Phosphotransferases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bulian, P., & Burger, J. (2015). The microenvironment in chronic lymphocytic leukemia: Biology and therapeutic translation. In Hodgkin and Non-Hodgkin Lymphomas Seen through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Vol. 2, pp. 56-71). Future Medicine Ltd.. https://doi.org/10.2217/fmeb2014.14.27

The microenvironment in chronic lymphocytic leukemia : Biology and therapeutic translation. / Bulian, Pietro; Burger, Jan.

Hodgkin and Non-Hodgkin Lymphomas Seen through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy. Vol. 2 Future Medicine Ltd., 2015. p. 56-71.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bulian, P & Burger, J 2015, The microenvironment in chronic lymphocytic leukemia: Biology and therapeutic translation. in Hodgkin and Non-Hodgkin Lymphomas Seen through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy. vol. 2, Future Medicine Ltd., pp. 56-71. https://doi.org/10.2217/fmeb2014.14.27
Bulian P, Burger J. The microenvironment in chronic lymphocytic leukemia: Biology and therapeutic translation. In Hodgkin and Non-Hodgkin Lymphomas Seen through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy. Vol. 2. Future Medicine Ltd. 2015. p. 56-71 https://doi.org/10.2217/fmeb2014.14.27
Bulian, Pietro ; Burger, Jan. / The microenvironment in chronic lymphocytic leukemia : Biology and therapeutic translation. Hodgkin and Non-Hodgkin Lymphomas Seen through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy. Vol. 2 Future Medicine Ltd., 2015. pp. 56-71
@inbook{f4396e43790f4b1a9ceb3d2af169fa7f,
title = "The microenvironment in chronic lymphocytic leukemia: Biology and therapeutic translation",
abstract = "The recent success of kinase inhibitors targeting the B cell receptor downstream molecules BTK (ibrutinib and PI3K (idelalisib), their characteristic clinical activity with chronic lymphocytic leukemia (CLL) cell redistribution from tissues into the blood, and their unique mechanism, interception of critical CLL - microenvironment interactions and signaling pathways, emphasize that the CLL microenvironment is a critical player in CLL pathogenesis and key for development of new targeted treatment approaches.",
author = "Pietro Bulian and Jan Burger",
year = "2015",
month = "6",
day = "1",
doi = "10.2217/fmeb2014.14.27",
language = "English",
isbn = "9781780845821",
volume = "2",
pages = "56--71",
booktitle = "Hodgkin and Non-Hodgkin Lymphomas Seen through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy",
publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - The microenvironment in chronic lymphocytic leukemia

T2 - Biology and therapeutic translation

AU - Bulian, Pietro

AU - Burger, Jan

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The recent success of kinase inhibitors targeting the B cell receptor downstream molecules BTK (ibrutinib and PI3K (idelalisib), their characteristic clinical activity with chronic lymphocytic leukemia (CLL) cell redistribution from tissues into the blood, and their unique mechanism, interception of critical CLL - microenvironment interactions and signaling pathways, emphasize that the CLL microenvironment is a critical player in CLL pathogenesis and key for development of new targeted treatment approaches.

AB - The recent success of kinase inhibitors targeting the B cell receptor downstream molecules BTK (ibrutinib and PI3K (idelalisib), their characteristic clinical activity with chronic lymphocytic leukemia (CLL) cell redistribution from tissues into the blood, and their unique mechanism, interception of critical CLL - microenvironment interactions and signaling pathways, emphasize that the CLL microenvironment is a critical player in CLL pathogenesis and key for development of new targeted treatment approaches.

UR - http://www.scopus.com/inward/record.url?scp=84957076990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957076990&partnerID=8YFLogxK

U2 - 10.2217/fmeb2014.14.27

DO - 10.2217/fmeb2014.14.27

M3 - Chapter

AN - SCOPUS:84957076990

SN - 9781780845821

SN - 9781780845845

VL - 2

SP - 56

EP - 71

BT - Hodgkin and Non-Hodgkin Lymphomas Seen through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy

PB - Future Medicine Ltd.

ER -